365 related articles for article (PubMed ID: 29057925)
1. Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL.
Karpel-Massler G; Ishida CT; Bianchetti E; Zhang Y; Shu C; Tsujiuchi T; Banu MA; Garcia F; Roth KA; Bruce JN; Canoll P; Siegelin MD
Nat Commun; 2017 Oct; 8(1):1067. PubMed ID: 29057925
[TBL] [Abstract][Full Text] [Related]
2. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.
Jin G; Reitman ZJ; Duncan CG; Spasojevic I; Gooden DM; Rasheed BA; Yang R; Lopez GY; He Y; McLendon RE; Bigner DD; Yan H
Cancer Res; 2013 Jan; 73(2):496-501. PubMed ID: 23204232
[TBL] [Abstract][Full Text] [Related]
3. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis.
Hlavac M; Dwucet A; Kast RE; Engelke J; Westhoff MA; Siegelin MD; Debatin KM; Wirtz CR; Halatsch ME; Karpel-Massler G
Cell Oncol (Dordr); 2019 Jun; 42(3):287-301. PubMed ID: 30859392
[TBL] [Abstract][Full Text] [Related]
5. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma.
Zhang Y; Ishida CT; Shu C; Kleiner G; Sanchez-Quintero MJ; Bianchetti E; Quinzii CM; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 May; 8(1):7373. PubMed ID: 29743557
[TBL] [Abstract][Full Text] [Related]
7. Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
Pusch S; Krausert S; Fischer V; Balss J; Ott M; Schrimpf D; Capper D; Sahm F; Eisel J; Beck AC; Jugold M; Eichwald V; Kaulfuss S; Panknin O; Rehwinkel H; Zimmermann K; Hillig RC; Guenther J; Toschi L; Neuhaus R; Haegebart A; Hess-Stumpp H; Bauser M; Wick W; Unterberg A; Herold-Mende C; Platten M; von Deimling A
Acta Neuropathol; 2017 Apr; 133(4):629-644. PubMed ID: 28124097
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.
van Lith SA; Navis AC; Lenting K; Verrijp K; Schepens JT; Hendriks WJ; Schubert NA; Venselaar H; Wevers RA; van Rooij A; Wesseling P; Molenaar RJ; van Noorden CJ; Pusch S; Tops B; Leenders WP
Sci Rep; 2016 Jul; 6():30486. PubMed ID: 27460417
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma.
Chuntova P; Yamamichi A; Chen T; Narayanaswamy R; Ronseaux S; Hudson C; Tron AE; Hyer ML; Montoya M; Mende AL; Nejo T; Downey KM; Diebold D; Lu M; Nicolay B; Okada H
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35606087
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Metabolomic Analysis of IDH1
Miyata S; Tominaga K; Sakashita E; Urabe M; Onuki Y; Gomi A; Yamaguchi T; Mieno M; Mizukami H; Kume A; Ozawa K; Watanabe E; Kawai K; Endo H
Sci Rep; 2019 Jul; 9(1):9787. PubMed ID: 31278288
[TBL] [Abstract][Full Text] [Related]
11. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
[TBL] [Abstract][Full Text] [Related]
12. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
[TBL] [Abstract][Full Text] [Related]
13. C-terminally truncated form of αB-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma.
Avliyakulov NK; Rajavel KS; Le KM; Guo L; Mirsadraei L; Yong WH; Liau LM; Li S; Lai A; Nghiemphu PL; Cloughesy TF; Linetsky M; Haykinson MJ; Pope WB
J Neurooncol; 2014 Mar; 117(1):53-65. PubMed ID: 24473683
[TBL] [Abstract][Full Text] [Related]
14. A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.
Machida Y; Nakagawa M; Matsunaga H; Yamaguchi M; Ogawara Y; Shima Y; Yamagata K; Katsumoto T; Hattori A; Itoh M; Seki T; Nishiya Y; Nakamura K; Suzuki K; Imaoka T; Baba D; Suzuki M; Sampetrean O; Saya H; Ichimura K; Kitabayashi I
Mol Cancer Ther; 2020 Feb; 19(2):375-383. PubMed ID: 31727689
[TBL] [Abstract][Full Text] [Related]
15. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM
J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945
[TBL] [Abstract][Full Text] [Related]
16. Different Effects of RNAi-Mediated Downregulation or Chemical Inhibition of NAMPT in an Isogenic IDH Mutant and Wild-Type Glioma Cell Model.
Clausing M; William D; Preussler M; Biedermann J; Grützmann K; Richter S; Buchholz F; Temme A; Schröck E; Klink B
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628596
[TBL] [Abstract][Full Text] [Related]
17. Isocitrate dehydrogenase mutations in gliomas.
Waitkus MS; Diplas BH; Yan H
Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
[TBL] [Abstract][Full Text] [Related]
18. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
Ohka F; Ito M; Ranjit M; Senga T; Motomura A; Motomura K; Saito K; Kato K; Kato Y; Wakabayashi T; Soga T; Natsume A
Tumour Biol; 2014 Jun; 35(6):5911-20. PubMed ID: 24590270
[TBL] [Abstract][Full Text] [Related]
19. Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells.
Hujber Z; Petővári G; Szoboszlai N; Dankó T; Nagy N; Kriston C; Krencz I; Paku S; Ozohanics O; Drahos L; Jeney A; Sebestyén A
J Exp Clin Cancer Res; 2017 Jun; 36(1):74. PubMed ID: 28578659
[TBL] [Abstract][Full Text] [Related]
20. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
